- Home
- AMWL vs CRVS Comparison
AMWL vs CRVS Comparison
Compare AMWL & CRVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AMWL
- CRVS
- Stock Information
- Founded
- AMWL 2006
- CRVS 2014
- Country
- AMWL United States
- CRVS United States
- Employees
- AMWL N/A
- CRVS N/A
- Industry
- AMWL Retail: Computer Software & Peripheral Equipment
- CRVS Biotechnology: Pharmaceutical Preparations
- Sector
- AMWL Technology
- CRVS Health Care
- Exchange
- AMWL Nasdaq
- CRVS Nasdaq
- Market Cap
- AMWL 165.7M
- CRVS 161.4M
- IPO Year
- AMWL 2020
- CRVS 2016
- Fundamental
- Price
- AMWL $8.91
- CRVS $5.04
- Analyst Decision
- AMWL Hold
- CRVS Buy
- Analyst Count
- AMWL 4
- CRVS 3
- Target Price
- AMWL $15.67
- CRVS $5.75
- AVG Volume (30 Days)
- AMWL 49.3K
- CRVS 385.2K
- Earning Date
- AMWL 10-30-2024
- CRVS 11-05-2024
- Dividend Yield
- AMWL N/A
- CRVS N/A
- EPS Growth
- AMWL N/A
- CRVS N/A
- EPS
- AMWL N/A
- CRVS N/A
- Revenue
- AMWL $254,911,000.00
- CRVS N/A
- Revenue This Year
- AMWL $3.68
- CRVS N/A
- Revenue Next Year
- AMWL $24.78
- CRVS N/A
- P/E Ratio
- AMWL N/A
- CRVS N/A
- Revenue Growth
- AMWL N/A
- CRVS N/A
- 52 Week Low
- AMWL $5.00
- CRVS $1.05
- 52 Week High
- AMWL $31.60
- CRVS $5.19
- Technical
- Relative Strength Index (RSI)
- AMWL 53.36
- CRVS 73.92
- Support Level
- AMWL $7.80
- CRVS $3.90
- Resistance Level
- AMWL $8.62
- CRVS $4.75
- Average True Range (ATR)
- AMWL 0.36
- CRVS 0.36
- MACD
- AMWL 0.03
- CRVS 0.04
- Stochastic Oscillator
- AMWL 60.77
- CRVS 93.44
About AMWL American Well Corporation
American Well Corp is a telehealth company enabling digital delivery of care for its customers. Its platform, Amwell, digital care delivery solution that equips health systems, health plans, government, and innovator clients with the tools to enable new models of care for their patients and members enabling care delivery across the full healthcare continuum - from primary and urgent care in the home to high acuity specialty consults, such as telestroke and telepsychiatry, in the hospital. It provides both on-demand and scheduled consultations. Its Health Plan Programs include Virtual Primary Care, Musculoskeletal Care, Dermatology Care, and Chronic Care among others.
About CRVS Corvus Pharmaceuticals Inc.
Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical engaged in developing drugs and antibodies that target the critical cellular elements of the immune system. It focuses on the development of immune modulator product candidates to treat COVID-19, T-cell lymphomas, other cancers, and autoimmune diseases. The company's primary product candidate is Soquelitinib (CPI-818), an oral, small-molecule drug that selectively inhibits ITK (interleukin-2-inducible T cell kinase). The other products include Ciforadenant (CPI-444) and Mupadolimab (CPI-006).